Pharmacogenetics of CYP-Mediated Drug Metabolism
Cytochrome P450 (CYP) enzymes are responsible for metabolism of approximately 75% of all drugs. Variation in CYP genes that code for CYP enzymes can predict how a person will metabolize specific drugs. This presentation describes pharmacogenetics of CYPs and models for clinical implementation.
Originally presented on June 30, 2016 in Salt Lake City, Utah.
Gwendolyn A. McMillin, PhD
Medical Director, Toxicology, ARUP Laboratories
Co-Medical Director, Pharmacogenetics, ARUP Laboratories
Professor of Pathology, University of Utah School of Medicine
Dr. McMillin is a professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. Dr. McMillin is actively involved in professional associations such as the International Association of Therapeutic Drug Monitoring and Clinical Chemistry (IATDMCT), the American Association for Clinical Chemistry (AACC), and the College of American Pathologists (CAP). Her primary interests include detection of neonatal drug exposures, as well as clinical applications and implementation of pharmacogenomics.
After this presentation, participants will be able to:
- Describe the role of drug metabolism in the activation and inactivation of drugs.
- Explain the nomenclature of cytochrome P450 enzyme phenotypes and genetic variants.
- List examples of CYPs and drugs with pharmacogenetic associations, and how they would be used to guide drug and dose selection.
University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories